4 天之前 · IRLAB’s unique and resource efficient research method, the Integrative Screening Process (ISP), generates the company’s drug pipeline. This proprietary platform is built on a systems pharmacology discovery approach with an extensive, world unique, standardized database on CNS compounds and classes collected over 25 years.

Rooted in Nobel Prize-winning research, IRLAB has grown rapidly to become recognized and respected as a world-leader in understanding the complex neuropharmacology of CNS disorders and especially Parkinson’s disease.

2025年1月31日 · IRLAB's drug candidate IRL757 has shown positive effects in several preclinical models of cognitive function, including improved motivation.

2025年2月12日 · Gothenburg, Sweden, February 12, 2024 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company’s full-year report for the period January-December 2024, has been published.

2025年3月11日 · February 6, 2024 IRLAB’s pioneering Phase IIb study with pirepemat – React-PD – provides new insights in specific Parkinson’s patient population and enables a data driven prediction of study timelines

Göteborg den 12 februari 2024 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett bolag som upptäcker och utvecklar nya behandlingar vid Parkinsons sjukdom, meddelade idag att bolagets bokslutskommuniké för perioden januari-december 2024 är publicerad.

candidates holding the potential to become first-in-class treatments that can transform the lives of millions of people worldwide, along with their loved ones. With the progress we have achieved so far and the exciting opportunities ahead, I confidently look forward to leading IRLAB into the next phase of our growth journey.”

Om IRLAB. Med grunden i Nobelprisvinnande forskning har IRLAB vuxit snabbt och är numera erkänt och respekterat som världsledande när det gäller att förstå den komplexa neurofarmakologin bakom CNS-sjukdomar, särskilt Parkinsons sjukdom.

Gothenburg, Sweden, January 14, 2025 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company that discovers and develops new treatments for Parkinson’s disease, today announces that all patients enrolled in the Phase IIb study with the drug candidate pirepemat (REACT-PD) have completed their final follow-up visit.

2023年1月17日 · IRLAB discovers and develops novel treatments of Parkinson’s disease and other CNS disorders. The company's most advanced drug candidates, mesdopetam (IRL790) and pirepemat (IRL752), are in Phase IIb and are designed to treat some of the most difficult symptoms related to Parkinson's.